The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: The re-emergence and fall of niacin

European Heart Journal

Volumn 34, Issue 17, 2013, Pages 1254-1257

  Landmesser, Ulf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; G PROTEIN COUPLED RECEPTOR; GPR109A RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN E2; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FLUSHING; HEART INFARCTION; HEART PROTECTION; HUMAN; LONG TERM CARE; MYOPATHY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ARTERIAL OCCLUSIVE DISEASES; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; MUSCULAR DISEASES; NIACIN;

EID: 84877257207     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht064     Document Type: Review

References (20)

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
2. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955;54:558-559.
3. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
4. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355.
5. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-3640.
6. Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, Tunaru S, Wirth A, Offermanns S. Nicotinic acid-and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent pros-tanoid formation in mice. J Clin Invest 2010;120:2910-2919.
7. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011;121:1163-1173.
8. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81.
9. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122.
10. The HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
11. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
12. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Luscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-2708.
13. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-122.
14. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Luscher TF, Landmesser U. Altered activation of endothelial anti-and pro-apoptotic pathways by high-density lipopro-tein from patients with coronary artery disease: role of HDL-proteome remodeling. Circulation 2013;in press.
15. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. Hdl and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8: 222-232.
16. Song WL, Stubbe J, Ricciotti E, Alamuddin N, Ibrahim S, Crichton I, Prempeh M, Lawson JA, Wilensky RL, Rasmussen LM, Pure E, FitzGerald GA. Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans. J Clin Invest 2012;122: 1459-1468.
17. Philipose S, Konya V, Lazarevic M, Pasterk LM, Marsche G, Frank S Peskar BA, Heinemann A, Schuligoi R. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One 2012; 7:e40222.
18. Strack AM, Carballo-Jane E, Wang SP, Xue J, Ping X, McNamara LA, Thankappan A, Price O, Wolff M, Wu TJ, Kawka D, Mariano M, Burton C, Chang CH, Chen J, Menke J, Luell S, Zycband EI, Tong X, Raubertas R, Sparrow CP, Hubbard B, Woods J, O'Neill G, Waters MG, Sitlani A. Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis. J Lipid Res 2013;54:177-188.
19. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605.
20. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost 2009;7 Suppl 1:332-339.